alpha-glutamyltryptophan has been researched along with Angiogenesis, Pathologic in 2 studies
| Timeframe | Studies, this research(%) | All Research% |
|---|---|---|
| pre-1990 | 0 (0.00) | 18.7374 |
| 1990's | 0 (0.00) | 18.2507 |
| 2000's | 2 (100.00) | 29.6817 |
| 2010's | 0 (0.00) | 24.3611 |
| 2020's | 0 (0.00) | 2.80 |
| Authors | Studies |
|---|---|
| Blann, A; Christodoulos, K; Deplanque, G; Ganesan, TS; Harris, AL; Jones, PH; Madhusudan, S; Talbot, DC; Wellmann, S | 1 |
| Ferrario, A; Gill, PS; Gomer, CJ; Rucker, N; Schwarz, MA; von Tiehl, KF | 1 |
1 trial(s) available for alpha-glutamyltryptophan and Angiogenesis, Pathologic
| Article | Year |
|---|---|
Phase II trial of the antiangiogenic agent IM862 in metastatic renal cell carcinoma.
Topics: Adult; Aged; Angiogenesis Inhibitors; Bone Neoplasms; Carcinoma, Renal Cell; Dipeptides; Disease Progression; Female; Humans; Kidney Neoplasms; Liver Neoplasms; Lung Neoplasms; Lymphatic Metastasis; Male; Middle Aged; Neovascularization, Pathologic; Prospective Studies; Time Factors | 2004 |
1 other study(ies) available for alpha-glutamyltryptophan and Angiogenesis, Pathologic
| Article | Year |
|---|---|
Antiangiogenic treatment enhances photodynamic therapy responsiveness in a mouse mammary carcinoma.
Topics: Angiogenesis Inhibitors; Animals; Cell Hypoxia; Combined Modality Therapy; Cytokines; Dihematoporphyrin Ether; Dipeptides; DNA-Binding Proteins; Endothelial Growth Factors; Female; Hypoxia-Inducible Factor 1; Hypoxia-Inducible Factor 1, alpha Subunit; Lymphokines; Mammary Neoplasms, Experimental; Mice; Mice, Inbred C3H; Neoplasm Proteins; Neoplasm Transplantation; Neovascularization, Pathologic; Nuclear Proteins; Photochemotherapy; Photosensitizing Agents; RNA-Binding Proteins; Transcription Factors; Vascular Endothelial Growth Factor A; Vascular Endothelial Growth Factors | 2000 |